We can’t show the full text here under this license.
Once-weekly dulaglutide versus insulin glargine for type 2 diabetes in mostly Asian patients taking metformin or sulphonylurea: 52-week safety and effectiveness
Updated
Abstract
A total of 774 patients were enrolled in a 52-week study comparing dulaglutide to insulin glargine for type 2 diabetes management.
- Dulaglutide 1.5 mg showed a mean reduction in HbA1c of -18.9 mmol/mol (-1.73%) at 26 weeks, which was superior to the -12.7 mmol/mol (-1.16%) reduction with glargine.
- More patients achieved an HbA1c target of <53.0 mmol/mol (<7.0%) with dulaglutide 1.5 mg and 0.75 mg compared to glargine.
- Body weight decreased with dulaglutide treatment, while it increased with insulin glargine.
- The incidence of total hypoglycaemia was lower in patients receiving dulaglutide compared to those on glargine.
- Gastrointestinal issues, such as diarrhoea and nausea, were the most common adverse events associated with dulaglutide.
Simplified
Key numbers
-18.9 (0.73) mmol/mol (-1.73 [0.067]%)
HbA1c Change (Dulaglutide 1.5 mg)
Change from baseline at week 26 for dulaglutide 1.5 mg.
64.8%
HbA1c Target Achievement
Percentage of patients achieving HbA1c <53.0 mmol/mol at week 26.
-1.47 (0.197) kg
Weight Change (Dulaglutide 1.5 mg)
Change from baseline at week 26 for dulaglutide 1.5 mg.